Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.
This week: Methotrexate SC Injection
Natalie Soulsby, Head of Clinical Development, Ward MM
Historically the only options for treating rheumatoid arthritis or psoriasis with methotrexate was either orally in the form of a tablet or as an intramuscular injection.
There is now another option available in the form of a pre-filled syringe that is administered sub- cutaneously. The product is called Trexject and will be available from 1st April 2018.
Like the other methotrexate products dosing is ONCE a week. As the bioavailability of the SC dosing is higher than the oral formulation, a dose reduction may be needed when swapping over from the oral to the SC formulation.
The syringes are available in a variety of concentrations and have a colour coded plastic backstop.
The patient information leaflet is available from the following link:
Important instructions for handling methotrexate;
- Only staff trained in good handling technique can administer this medication
- Pregnant staff should avoid handling this medication
- Ensure disposable gloves are worn at all times when handling this medication
- Use a cytotoxic bin to dispose of all items used for administration or cleaning
- If accidental contact with skin or eye occurs, treat immediately by irrigating the area with a large quantity of water or sodium bicarbonate and seek medical attention
Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to firstname.lastname@example.org.